Sign in
Taking people in United StatesEarly phase 1

Tests C-peptide during low blood sugar in adults with type 1 diabetes

Tests C-peptide in adults with type 1 diabetes during insulin-induced low blood sugar.

Key facts

Who runs it
University of Cincinnati
Where
Cincinnati, United StatesSee the site
Trial code
Registry title
Effect of C-peptide on Hypoglycemic Counterregulation
Status
Recruiting
Phase
Early phase 1
People taking part
38 people, planned
Started
1 Jun 2024
Expected to end
1 Jan 2028
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Saline
  • C-peptide
Record updated
17 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 40 with a BMI under 30 kg/m2. It studies how C-peptide affects the body's response to low blood sugar.

Age
18 to 40 years
Sex
All sexes can join.

Main reasons for not taking part

  • Pregnant or breastfeeding women
  • Cigarette smoking
  • HIV or hepatitis
  • Cardiovascular disease
  • Microvascular disease

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • BMI less than 30 kg/m2

Who cannot take part

  • pregnant or lactating women cigarette smoking presence of HIV or hepatitis presence of cardiovascular disease presence of microvascular disease

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 40 years old?

Where in United States

  • University of CincinnatiCincinnati, United StatesContact: Jason Winnick, PhDTaking people

About the trial

What the trial wants to find out

Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose production and increases the depth and duration of hypoglycemic episodes. We have observed that the naturally occurring protein C-peptide increases glucagon secretion in dogs during insulin-induced hypoglycemia, which increases hepatic glucose production; the experiments in this application will shed light on the translation of this finding to the human.

The 4 groups in the trial

  • Healthy Control- SalinePlacebo, for comparison

    Saline will be infused in healthy control subjects during insulin-induced hypoglycemia

    Treatment: Saline

  • Healthy Control- C-peptideExisting treatment, for comparison

    C-peptide will be infused in healthy control subjects during insulin-induced hypoglycemia

    Treatment: C-peptide

  • T1D- SalinePlacebo, for comparison

    Saline will be infused in T1D subjects during insulin-induced hypoglycemia

    Treatment: Saline

  • T1D- C-peptideExisting treatment, for comparison

    C-peptide will be infused in T1D subjects during insulin-induced hypoglycemia

    Treatment: C-peptide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
On the Regulation of Hepatic Glucose Metabolism During Insulin-induced Hypoglycemia
Plain-language title
Tests C-peptide during low blood sugar in adults with type 1 diabetesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06470295, who can take part
Record updated
17 February 2026